CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared To Standard Of Care For Patients With Relapsed Or Refractory Multiple Myeloma
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared To Standard Of Care For Patients With Relapsed Or Refractory Multiple Myeloma . (MENAFN - GlobeNewsWire - Nasdaq)    89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI– after three-year follow-up in CARTITUDE-4 study; the majority ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108973898/CARVYKTI-Significantly-Improved-Minimal-Residual-Disease-Negativity-Compared-To-Standard-Of-Care-For-Patients-With-Relapsed-Or-Refractory-Multiple-Myeloma
2024-12-09
rss
(MENAFN - GlobeNewsWire - Nasdaq)    89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI– after three-year follow-up in CARTITUDE-4 study; the majority ...
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared To Standard Of Care For Patients With Relapsed Or Refractory Multiple Myeloma